A5103236032- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Genetic Associations and Epidemiology
- Lipid metabolism and disorders
- Hemoglobinopathies and Related Disorders
- Circular RNAs in diseases
- Acute Myocardial Infarction Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Venous Thromboembolism Diagnosis and Management
- Cytokine Signaling Pathways and Interactions
- Advanced biosensing and bioanalysis techniques
- Epigenetics and DNA Methylation
- Cancer Mechanisms and Therapy
- RNA Research and Splicing
23andMe (United States)
2018-2019
The University of Texas Southwestern Medical Center
2011-2015
Office of Basic Energy Sciences
2013
Southwestern Medical Center
2012-2013
NSCLC (non-small cell lung cancer) often exhibits resistance to paclitaxel treatment. Identifying the elements regulating response will advance efforts overcome such in therapy. Using vitro approaches, we demonstrated that over-expression of microRNA miR-337-3p sensitizes NCI-H1155 cells paclitaxel, and mimic has a general effect on lines, which may provide novel adjuvant strategy treatment cancer. By combining silico identified STAT3 RAP1A as direct targets mediate sensitivity. Further...
Lung cancer is the leading cause of cancer-related fatalities. Recent success developing genotypically targeted therapies, with potency only in well-defined subpopulations tumors, suggests a path to improving patient survival. We used library oligonucleotide inhibitors microRNAs, class posttranscriptional gene regulators, identify novel synthetic lethal interactions between miRNA inhibition and molecular mechanisms non-small cell lung (NSCLC). Two inhibitors, those for miR-92a miR-1226*,...
microRNAs (miRNAs) are small RNAs endogenously expressed in multiple organisms that regulate gene expression largely by decreasing levels of target messenger (mRNAs). Over the past few years, numerous studies have demonstrated critical roles for miRNAs pathogenesis many cancers, including lung cancer. Cellular miRNA can be easily manipulated, showing promise developing miRNA-targeted oligos as next-generation therapeutic agents. In a comprehensive effort to identify novel miRNA-based agents...
In this study, we perform a full genome-wide association study (GWAS) to identify statistically significantly associated single nucleotide polymorphisms (SNPs) with three red blood cell (RBC) components and follow it two independent PheWASs examine associations between phenotypic data (case-control status of diagnoses or disease), significant SNPs, RBC component levels. We first identified the components: mean platelet volume (MPV), corpuscular (MCV), counts (PC), genotypes approximately...
Article11 December 2015Open Access Source Data A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression Benjamin B Shields Departments of Cell Biology, University Texas Southwestern Medical Center, Dallas, TX, USA Search for more papers by this author Chad V Pecot Center RNA interference and Non-Coding RNA, MD Anderson Cancer Houston, Hua Gao Elizabeth McMillan Malia Potts Christa Nagel Obstetrics Gynecology, Scott Purinton Ying Wang Department...
Abstract We are addressing the questions of whether microRNAs (miRNAs) play a functional role in modulating drug sensitivity lung cancer cells, and miRNA expression levels can be manipulated to increase treatment. Using combination silico vitro approaches, we identified miR-337-3p as modulator paclitaxel NSCLC cell lines where over-expression sensitizes NCI-H1155 cells (>2 fold) docetaxel (>10 by enhancing taxane-induced mitotic arrest. Of several possible targets found that...
Abstract In this study, we perform a full genome-wide association study (GWAS) to identify statistically significantly associated single nucleotide polymorphisms (SNPs) with three red blood cell (RBC) components and follow it two independent PheWASs examine associations between phenotypic data (case-control status of diagnoses or disease), significant SNPs, RBC component levels. We first identified the components: mean platelet volume (MPV), corpuscular (MCV), counts (PC), genotypes...
Abstract Lung cancer, especially non-small cell lung cancer (NSCLC), is currently the leading cause of fatalities in United States, accounting for 30% males, and 26% females. Additionally, five-year survival rate individuals affected by has only improved 3% past 35 years. As suggested data, very few effective treatment options are available NSCLC, many vary dramatically efficacy depending on genetic status tumor. In particular, presence mutant KRAS NSCLC serves as a negative predictor drug...
Abstract Lung cancer is the leading cause of cancer-related deaths, with majority deaths due to failed therapy from tumor drug resistance. Third-generation chemotherapeutic agents represent standard first-line treatment for advanced small cell (SCLC) and non-small (NSCLC) lung patients. Response rates are poor (20-40%) a median survival 8-10 months. In an unbiased comprehensive approach, we have combined high-throughput screening platform library chemically synthesized microRNA mimics...